JPS5711987A - Novel imidazo-rifamycin derivative - Google Patents

Novel imidazo-rifamycin derivative

Info

Publication number
JPS5711987A
JPS5711987A JP7787781A JP7787781A JPS5711987A JP S5711987 A JPS5711987 A JP S5711987A JP 7787781 A JP7787781 A JP 7787781A JP 7787781 A JP7787781 A JP 7787781A JP S5711987 A JPS5711987 A JP S5711987A
Authority
JP
Japan
Prior art keywords
rifamycin derivative
novel imidazo
imidazo
novel
rifamycin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP7787781A
Other languages
English (en)
Japanese (ja)
Other versions
JPS6123192B2 (cg-RX-API-DMAC10.html
Inventor
Maruki Egideio
Montetsuki Rauretsuta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alfa Farmaceutici SpA
Original Assignee
Alfa Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfa Farmaceutici SpA filed Critical Alfa Farmaceutici SpA
Publication of JPS5711987A publication Critical patent/JPS5711987A/ja
Publication of JPS6123192B2 publication Critical patent/JPS6123192B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP7787781A 1980-05-22 1981-05-22 Novel imidazo-rifamycin derivative Granted JPS5711987A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT03429/80A IT1154655B (it) 1980-05-22 1980-05-22 Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica

Publications (2)

Publication Number Publication Date
JPS5711987A true JPS5711987A (en) 1982-01-21
JPS6123192B2 JPS6123192B2 (cg-RX-API-DMAC10.html) 1986-06-04

Family

ID=11107198

Family Applications (1)

Application Number Title Priority Date Filing Date
JP7787781A Granted JPS5711987A (en) 1980-05-22 1981-05-22 Novel imidazo-rifamycin derivative

Country Status (25)

Country Link
US (1) US4341785A (cg-RX-API-DMAC10.html)
JP (1) JPS5711987A (cg-RX-API-DMAC10.html)
AR (1) AR226212A1 (cg-RX-API-DMAC10.html)
AT (1) AT373599B (cg-RX-API-DMAC10.html)
AU (1) AU537093B2 (cg-RX-API-DMAC10.html)
BE (1) BE888895A (cg-RX-API-DMAC10.html)
CA (1) CA1142518A (cg-RX-API-DMAC10.html)
CH (1) CH648037A5 (cg-RX-API-DMAC10.html)
DE (1) DE3120460A1 (cg-RX-API-DMAC10.html)
DK (1) DK157876C (cg-RX-API-DMAC10.html)
EG (1) EG14891A (cg-RX-API-DMAC10.html)
ES (1) ES502906A0 (cg-RX-API-DMAC10.html)
FI (1) FI69467C (cg-RX-API-DMAC10.html)
FR (1) FR2482967A1 (cg-RX-API-DMAC10.html)
GB (1) GB2079270B (cg-RX-API-DMAC10.html)
GR (1) GR75640B (cg-RX-API-DMAC10.html)
IE (1) IE51204B1 (cg-RX-API-DMAC10.html)
IT (1) IT1154655B (cg-RX-API-DMAC10.html)
LU (1) LU83376A1 (cg-RX-API-DMAC10.html)
NL (1) NL187022C (cg-RX-API-DMAC10.html)
NO (1) NO155622C (cg-RX-API-DMAC10.html)
PH (2) PH17207A (cg-RX-API-DMAC10.html)
PT (1) PT73064B (cg-RX-API-DMAC10.html)
SE (1) SE453089B (cg-RX-API-DMAC10.html)
ZA (1) ZA813430B (cg-RX-API-DMAC10.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007509904A (ja) * 2003-11-07 2007-04-19 アルファ ワッセルマン ソシエタ ペル アチオニ リファキシミンの多形体、それらの製造方法および医薬製剤におけるそれらの使用
JP2008531623A (ja) * 2005-03-03 2008-08-14 アルファ ワッセルマン ソシエタ ペル アチオニ リファキシミンの新規多形、その製造方法、及び医薬製剤中でのその使用
JP2015509105A (ja) * 2012-01-25 2015-03-26 サリックス ファーマスーティカルズ，リミテッド リファキシミン誘導体及びその使用
JP2017515821A (ja) * 2014-05-12 2017-06-15 アルファ ワッセルマン ソシエタ ペル アチオニＡｌｆａ Ｗａｓｓｅｒｍａｎｎ Ｓ．Ｐ．Ａ． リファキシミンの新規溶媒和物結晶形、生成物、組成物及びそれらの使用

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1199374B (it) * 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
IT1264494B1 (it) * 1993-03-23 1996-09-24 Alfa Wassermann Spa Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter
US7048906B2 (en) * 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US5981522A (en) * 1995-09-01 1999-11-09 Kaneka Corporation Treatment of disease caused by infection of Helicobacter
KR100407851B1 (ko) * 1997-02-28 2004-04-29 가네가후치 가가쿠고교 가부시키가이샤 헬리코박터의감염에기인하는질환치료제
AU2002360416A1 (en) * 2001-11-21 2003-06-10 Activbiotics, Inc. Targeted therapeutics and uses thereof
AU2002364162A1 (en) * 2001-12-13 2003-06-30 Activbiotics, Inc. Sulfhydryl rifamycins and uses thereof
WO2004041240A1 (en) * 2002-11-05 2004-05-21 Piero Chiarelli Controlled and continued delivery of rifaximin and/or other substances
US7820652B2 (en) * 2003-09-24 2010-10-26 Activbiotics Pharma, Llc Regimen for the administration of rifamycin-class antibiotics
US7906542B2 (en) * 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
US20080262024A1 (en) * 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
US7923553B2 (en) * 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
US7902206B2 (en) * 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
US7265107B2 (en) * 2004-03-10 2007-09-04 Cumbre Pharmaceuticals Inc. Rifamycin C-11 oxime cyclo derivatives effective against drug-resistant microbes
US7256187B2 (en) * 2004-03-10 2007-08-14 Cumbre Pharmaceuticals Inc. Rifamycin C-11 oxime derivatives effective against drug-resistant microbes
US7202246B2 (en) * 2004-06-09 2007-04-10 Cumbre Pharmaceuticals Inc. Spiro-rifamycin derivatives targeting RNA polymerase
US20060210492A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Use of rifaximin for treatment and prevention of periodontal conditions
US20060210483A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
US8003118B2 (en) * 2005-03-02 2011-08-23 Kodsi Robert E Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
ITBO20050123A1 (it) * 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
EP1928890B1 (en) 2005-08-11 2013-04-03 Targanta Therapeutics Inc. Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections
CA2643364C (en) 2006-03-09 2017-06-06 Salix Pharmaceuticals, Inc. Rifaximin anti-rectal dysfunction preparation
JP5844961B2 (ja) 2006-08-02 2016-01-20 サリックス ファーマシューティカルズ， インコーポレイテッド 放射線直腸ｓ状結腸炎を処置するための組成物および方法
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
AU2007298733B2 (en) * 2006-09-22 2012-11-08 Cipla Limited Rifaximin
US20080159987A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Restless Legs Syndrome
US20080161337A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Chronic Prostatitis
ITMI20071241A1 (it) * 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
JP5755878B2 (ja) 2007-07-06 2015-07-29 ルパン リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ リファキシミンの薬剤組成物
EP3714878B1 (en) 2007-07-06 2022-01-19 Lupin Limited Pharmaceutical compositions of rifaximin
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
CN104650114A (zh) 2008-02-25 2015-05-27 萨利克斯药品有限公司 利福昔明的多种形式及其用途
US11779571B2 (en) 2008-02-26 2023-10-10 Salix Pharmaceuticals, Inc. Methods for treating irritable bowel syndrome (IBS)
KR20100122937A (ko) 2008-02-26 2010-11-23 샐릭스 파마슈티컬스 리미티드 장 질환의 치료 방법
PT2294012E (pt) 2008-05-07 2014-10-15 Salix Pharmaceuticals Ltd Administração de um agente de limpeza intestinal e de um antibiótico para o tratamento de doença intestinal
EP2324041A4 (en) 2008-08-13 2012-06-13 Targanta Therapeutics Corp PHOSPHONIZED RIFAMYCINS AND ITS APPLICATION FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS
RU2011116400A (ru) 2008-09-26 2012-11-10 Аска Фармасьютикал Ко., Лтд. (Jp) Средство для предотвращения и/или лечения функционального расстройства желудочно-кишечного тракта
AU2009298389C1 (en) 2008-10-02 2016-04-28 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US12285414B2 (en) 2008-10-02 2025-04-29 Salix Pharmaceuticals, Inc. Methods of treating hepatic encephalopathy
ES2718614T3 (es) 2008-12-10 2019-07-03 Cipla Ltd Complejos de rifaximina
IT1397617B1 (it) * 2009-04-20 2013-01-18 Alfa Wassermann Spa Nuovi derivati della rifamicina
BRPI1010028A2 (pt) 2009-06-02 2019-02-12 Salix Pharmaceuticals, Ltd. métodos de tratamento de encefalopatia hepática
AU2010292043B2 (en) 2009-09-13 2016-02-25 Salix Pharmaceuticals, Ltd. Methods for treating irritable bowel syndrome (IBS)
WO2011051971A2 (en) 2009-10-27 2011-05-05 Lupin Limited Solid dispersion of rifaximin
EP2503989A2 (en) 2009-11-23 2012-10-03 Cipla Limited Topical foam composition
EP2401282B2 (en) 2009-12-28 2017-01-04 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
EP2536282A4 (en) 2010-02-18 2013-07-03 Salix Pharmaceuticals Ltd METHOD FOR THE TREATMENT OF INFECTIONS
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
AU2011225810B2 (en) 2010-03-10 2014-11-06 Lupin Limited Rifaximin ready-to-use suspension
SG186981A1 (en) 2010-07-12 2013-02-28 Salix Pharmaceuticals Ltd Formulations of rifaximin and uses thereof
WO2012035544A2 (en) 2010-09-13 2012-03-22 Sequent Scientific Ltd. A novel polymorphic form of rifaximin and process for its preparation
CA2825964A1 (en) 2011-02-11 2012-08-16 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
AU2012251385A1 (en) 2011-05-02 2013-11-21 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
ITMI20110890A1 (it) 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
RU2496475C2 (ru) 2011-10-26 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция и набор для лечения бактериальных инфекций
US20130184302A1 (en) 2011-11-02 2013-07-18 Enoch Bortey Methods for treating irritable bowel syndrome (ibs) and infections
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
WO2014091432A1 (en) 2012-12-12 2014-06-19 Ranbaxy Laboratories Limited Pharmaceutical compositions of rifaximin
JP2016516988A (ja) 2013-03-15 2016-06-09 アルファ ワッセルマン ソシエタ ペル アチオニＡｌｆａ Ｗａｓｓｅｒｍａｎｎ Ｓ．Ｐ．Ａ． 膣感染症を診断するための方法
MX2015011802A (es) 2013-03-15 2016-01-08 Alfa Wassermann Spa Rifaximina para usarse en el tratamiento de infecciones vaginales.
PL2983647T3 (pl) 2013-04-12 2021-01-25 Alfasigma S.P.A. Podawanie nlpz oraz związane z tym składniki, sposoby i układy
US9018225B1 (en) 2013-07-26 2015-04-28 Novel Laboratories Rifaximin crystalline forms and methods of preparation thereof
EP2927235B1 (en) 2014-03-31 2017-02-08 Euticals S.P.A. Polymorphic mixture of rifaximin and its use for the preparation of solid formulations
CA2946101A1 (en) * 2014-04-19 2015-10-22 Granules India Limited An improved process for the preparation of rifamycin derivatives
WO2015171493A1 (en) 2014-05-04 2015-11-12 Salix Pharmaceuticals, Inc. Ibs microbiota and uses thereof
EP2982764A1 (en) 2014-08-05 2016-02-10 ALFA WASSERMANN S.p.A. Identification of vaginal bacteria
US9988398B2 (en) 2016-06-07 2018-06-05 Cadila Healthcare Limited Crystalline form of rifaximin and process for its preparation
KR102494049B1 (ko) 2016-09-30 2023-01-31 샐릭스 파마슈티컬스 인코포레이티드 리팍시민의 고체 분산물 형태
IT201700091912A1 (it) * 2017-08-08 2019-02-08 Biofer Spa Nuove pirido-imidazo rifamicine
DK3645539T3 (da) * 2017-06-26 2021-05-10 Biofer Spa Pyrido-imidazo-rifamycin-derivater som antibakterielt middel

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE273377C (cg-RX-API-DMAC10.html) *
AT273377B (de) * 1967-03-01 1969-08-11 Lepetit Spa Verfahren zur Herstellung von neuen Rifamycinen
AT344898B (de) * 1975-06-13 1978-08-10 Archifar Ind Chim Trentino Verfahren zur herstellung neuer rifamycin-verbindungen
DK345977A (da) * 1976-09-30 1978-03-31 Archifar Ind Chim Trentino G rifamycinforbindelser og fremgangsmaade til deres fremstillin
CH629212A5 (it) * 1976-10-18 1982-04-15 Erba Farmitalia Procedimento per la preparazione di composti di rifamicina.
CH633014A5 (en) * 1978-06-09 1982-11-15 Erba Farmitalia Rifamycin compounds

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007509904A (ja) * 2003-11-07 2007-04-19 アルファ ワッセルマン ソシエタ ペル アチオニ リファキシミンの多形体、それらの製造方法および医薬製剤におけるそれらの使用
JP2011046738A (ja) * 2003-11-07 2011-03-10 Alfa Wassermann Spa リファキシミンの多形体、それらの製造方法および医薬製剤におけるそれらの使用
JP2014177500A (ja) * 2003-11-07 2014-09-25 Alfa Wassermann Spa リファキシミンの多形体、それらの製造方法および医薬製剤におけるそれらの使用
JP2008531623A (ja) * 2005-03-03 2008-08-14 アルファ ワッセルマン ソシエタ ペル アチオニ リファキシミンの新規多形、その製造方法、及び医薬製剤中でのその使用
JP2013216710A (ja) * 2005-03-03 2013-10-24 Alfa Wassermann Spa リファキシミンの新規多形、その製造方法、及び医薬製剤中でのその使用
JP2015509105A (ja) * 2012-01-25 2015-03-26 サリックス ファーマスーティカルズ，リミテッド リファキシミン誘導体及びその使用
JP2017515821A (ja) * 2014-05-12 2017-06-15 アルファ ワッセルマン ソシエタ ペル アチオニＡｌｆａ Ｗａｓｓｅｒｍａｎｎ Ｓ．Ｐ．Ａ． リファキシミンの新規溶媒和物結晶形、生成物、組成物及びそれらの使用

Also Published As

Publication number Publication date
FR2482967B1 (cg-RX-API-DMAC10.html) 1985-03-29
NO155622B (no) 1987-01-19
DK157876B (da) 1990-02-26
GB2079270B (en) 1984-01-18
DE3120460A1 (de) 1982-03-11
US4341785A (en) 1982-07-27
IT8003429A0 (it) 1980-05-22
FI811565L (fi) 1981-11-23
FI69467C (fi) 1986-02-10
NL187022C (nl) 1991-05-01
PT73064B (en) 1982-07-05
AR226212A1 (es) 1982-06-15
NL8102290A (nl) 1981-12-16
AU7065581A (en) 1981-11-26
ATA222781A (de) 1983-06-15
PT73064A (en) 1981-06-01
DE3120460C2 (cg-RX-API-DMAC10.html) 1990-12-13
SE453089B (sv) 1988-01-11
AU537093B2 (en) 1984-06-07
SE8103216L (sv) 1981-11-23
FR2482967A1 (fr) 1981-11-27
ES8203388A1 (es) 1982-04-01
PH17207A (en) 1984-06-19
CA1142518A (en) 1983-03-08
PH18704A (en) 1985-09-05
IE51204B1 (en) 1986-10-29
DK157876C (da) 1990-07-30
IE811139L (en) 1981-11-22
CH648037A5 (de) 1985-02-28
LU83376A1 (fr) 1981-09-11
NL187022B (nl) 1990-12-03
EG14891A (en) 1985-12-31
GR75640B (cg-RX-API-DMAC10.html) 1984-08-02
GB2079270A (en) 1982-01-20
ES502906A0 (es) 1982-04-01
AT373599B (de) 1984-02-10
JPS6123192B2 (cg-RX-API-DMAC10.html) 1986-06-04
NO811731L (no) 1981-11-23
NO155622C (no) 1987-04-29
FI69467B (fi) 1985-10-31
BE888895A (fr) 1981-09-16
DK224781A (da) 1981-11-23
ZA813430B (en) 1982-06-30
IT1154655B (it) 1987-01-21

Similar Documents

Publication Publication Date Title
JPS5711987A (en) Novel imidazo-rifamycin derivative
ZA816809B (en) Aminoalkylfuran derivative
JPS5785379A (en) 3-aryl-5-isothiazole derivative
GB2086380B (en) L-argininal derivatives
JPS56150050A (en) Oxitocin derivative
JPS5718681A (en) Novel triazoloquinoxalin-4-one
JPS5781476A (en) Isooxazolylbenzamide derivative
GB2075499B (en) Nonaprenylamine derivatives
GB2083462B (en) 2-thiopenem derivatives
GB2088365B (en) Moranoline derivative
PH18633A (en) Novel antrancyclinone derivative
GB2067989B (en) Bis-moranoline derivatives
JPS577467A (en) Novel phenylpropargylamine derivative
GB2089792B (en) Substituted benzopyranotriazoles
GB2088379B (en) 1-phenethylimidazole derivatives
JPS5793949A (en) Alpha-cyanophenoxybenzylamine derivative
GB2076815B (en) Aminophenylpyridine derivatives
GB2085882B (en) Aprosamine derivatives
GB2070589B (en) 7a1methoxycephalospin derivatives
GB2076395B (en) Nonaprenylamine derivatives
GB2074165B (en) Nonaprenylamine derivatives
GB2073201B (en) Steroid-spiro-oxathiazolidine derivatives
JPS5795981A (en) Novel dibenzopyrane derivative
JPS57118540A (en) Bis-aminomethyl-anthraquinone derivative
JPS56133270A (en) Substituted phenoxy-aminopropanol derivative